Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.60 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.60 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.60 |
| ▸ | MGAM | O43451 | 7/20 | 0.58 |
| ▸ | GAA | P10253 | 7/20 | 0.58 |
| ▸ | SI | P14410 | 7/20 | 0.58 |
| ▸ | MGAM2 | Q2M2H8 | 7/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL2380188 | 1.00 | CSNK2A2 (0.60) | CSNK2A2CSNK2BCSNK2A1MGAMGAA | |
| SCHEMBL45441 | 0.89 | KDM4E (0.67) | CSNK2A2CSNK2BCSNK2A1MGAMGAA | |
| Hydrochloric Acid SCHEMBL3691525 | 0.87 | KDM4E (0.64) | CSNK2A2CSNK2BCSNK2A1MGAMGAA | |
| Phosphoric Acid SCHEMBL16033968 | 0.86 | CSNK2A2 (0.60) | CSNK2A2CSNK2BCSNK2A1MGAMGAA | |
| SCHEMBL6538646 | 0.85 | KDM4E (0.66) | CSNK2A2CSNK2BCSNK2A1MGAMGAA | |
| SCHEMBL28206720 | 0.80 | KDM4E (0.57) | CSNK2A2CSNK2BCSNK2A1MGAMGAA | |
| SCHEMBL10692885 | 0.79 | PIK3CA (0.57) | CSNK2A2CSNK2BCSNK2A1MGAMGAA | |
| SCHEMBL7324357 | 0.75 | CSNK2A1 (1.00) | CSNK2A2CSNK2BCSNK2A1MGAMGAA | |
| SCHEMBL11431183 | 0.74 | MGAM (0.68) | CSNK2A2CSNK2BCSNK2A1MGAMGAA | |
| SCHEMBL17713894 | 0.74 | ALDH1A1 (0.61) | CSNK2A2CSNK2BCSNK2A1MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-09 | — | — | US | disclosed |
| US-9475782-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | disclosed |
| US-8604025-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT LABORATORIES (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130267537-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8481576-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8431604-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8367661-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120232092-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. | 2012-09-13 | — | — | US | disclosed |
| US-8202859-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20050131236-A1 | Novel diazabicyclic biaryl derivatives | ANIONA APS (DK) | 2005-06-16 | — | — | US | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005028477-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETY LCHOLINE RECEPTORS | ABBOTT LABORATORIES (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | ABBOTT LABORATORIES | 2005-03-24 | — | — | US | disclosed |
| EP-1506200-A2 | NOVEL DIAZABICYCLIC BIARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004086865-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004029053-A1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2004-04-08 | — | — | WO | disclosed |
| WO-2003094831-A2 | NOVEL DIAZABICYCLIC BIARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2003-11-20 | — | — | WO | disclosed |
| US-20030134859-A1 | PPAR-gamma modulator | SANKYO COMPANY, LIMITED (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1277729-A1 | PPAR (GAMMA) MODULATORS | Sankyo Company, Limited (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267537-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | CSNK2A2 458/4885CSNK2B 650/4885CSNK2A1 690/4885 |
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | CSNK2A2 4366/4885CSNK2B 4287/4885CSNK2A1 4362/4885 |
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, GRK5 | CSNK2A2 4142/4885CSNK2B 4020/4885CSNK2A1 4137/4885 |
| US-20120232092-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | CSNK2A2 458/4885CSNK2B 650/4885CSNK2A1 690/4885 |
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | CHRNA7, CHRNA1, CHRNA5 | CSNK2A2 269/4885CSNK2B 358/4885CSNK2A1 206/4885 |
| US-20030134859-A1 | PPAR-gamma modulator | PPARG, PPARA, PPARD | CSNK2A2 1128/4885CSNK2B 638/4885CSNK2A1 1010/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | CSNK2A2 1337/4885CSNK2B 1505/4885CSNK2A1 1182/4885 |
| US-20050131236-A1 | Novel diazabicyclic biaryl derivatives | CHRNA6, CHRNA3, CHRNA2 | CSNK2A2 2310/4885CSNK2B 2325/4885CSNK2A1 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.